Standing on the cusp of something great: How real-world data is poised to transform cancer care
cancer, Drug regulation, IQVIA, Oncology, patient data, pharma, Real World Evidence
0 Comment
Drug regulation
Despite progress, Brexit still threatens UK with relegation to second division
ABPI, BIA, Brexit, Drug regulation, EMIG, IMDRF
0 Comment
With time running out on Brexit, companies are already making long-term decisions.
Accessing biosimilars: untapped potential in EU and US
biosimilars, drug market access, Drug regulation, market access, regulatory pathway
0 Comment
Though they can reduce the costs of health care, biosimilars still face challenges to access.
Huge scale of Brexit threat to Europe’s medicines supplies revealed
Brexit, Drug regulation, EFPIA, ema, Medicines access
0 Comment
New survey reveals the huge task facing pharma in keeping medicines moving around Europe after Brexit.
PRIME movers: taking stock of the EMA’s scheme
drug market access, Drug regulation, ema, European Medicines Agency, market access, PRIME scheme
0 Comment
Taking stock of one PRIME, of the EMA’s flagship market access initiatives.
New UK law to control generic drug prices – implications for pharma
Drug pricing, Drug regulation, market access, NHS, UK government
0 Comment
The aims and implications of the Health Service Medical Supplies (Costs) Act 2017.